Important update to Galapagos’ invitation to its ordinary and extraordinary shareholders’ meetings
April 16 2020 - 7:04PM
Important update to Galapagos’ invitation to its ordinary and
extraordinary shareholders’ meetings
Mechelen, Belgium; 17 April 2020, 01.15
CET; regulated information – In light of the ongoing COVID-19
pandemic, Galapagos NV (Euronext & NASDAQ: GLPG) will hold its
shareholders’ meetings behind closed doors, with shareholder
participation in advance only.
Out of safety precautions against the COVID-19
pandemic, and in accordance with the Royal Decree No. 4 under
special powers published on 9 April 2020, the physical presence of
shareholders, proxyholders, holders of subscription rights or other
persons otherwise entitled to attend the shareholders’ meeting will
be prohibited at Galapagos’ annual (ordinary) and extraordinary
shareholders’ meetings scheduled for Tuesday 28 April 2020 at 2:00
p.m. (CET).
Shareholders are kindly invited and strongly
encouraged to vote prior to the meetings, either by voting form or
by proxy.
Please note the following alternative
arrangements for the meetings:
(1) Proxies can
only be granted to the general counsel. An updated proxy form is
available on our website, under the tab “Investors > Shareholder
Information > Shareholders’ Meetings > Proxy form”.
If
a proxy has already been received on the date and time of this
press release in which a different proxy holder is appointed, the
votes or abstentions will still be taken into account if the proxy
contains specific voting instructions, and without this other proxy
holder having to be present at the meetings;
(2)
Voting forms and proxies must reach Galapagos before or on or 24
April 2020 at midnight CET at the latest.
An
updated voting form is available on our website, under the tab
“Investors > Shareholder Information > Shareholders’ Meetings
> Voting form”. If a voting form has already been received on
the date and time of this press release, the votes or abstentions
will still be taken into
account;
- Only written questions may be submitted and must
reach Galapagos before or on or 24 April 2020 at midnight CET at
the latest. Answers will be published on our website at the latest
prior to the vote;
- Both meetings will be held at the offices of Van Halteren
notaires - notarissen, de Lignestraat 13, 1000 Brussels, instead of
Galapagos’ registered office.
It
is strongly recommended to use e-mail (shareholders@glpg.com) only
for all communications regarding the shareholders’ meetings, as
postal services may be disrupted due to the pandemic. Please also
note that the above mentioned Royal Decree exempts us from keeping
the (updated) documents pertaining to the meetings physically
available at our registered office or providing them by post.
The above mentioned arrangements prevail over
the arrangements with the same subject as described in the
convening notice, published on our website on 27 March 2020. An
updated attendance notification form, taking into account that only
voting prior to the meetings is allowed, is available on our
website, under the tab “Investors > Shareholder Information >
Shareholders’ Meetings > Attendance notification form”.
An updated convening notice and other documents
pertaining to the shareholders’ meetings, including all details
regarding the meetings’ procedures, can be consulted on our
website, at www.glpg.com/shareholders-meetings. The Investor
Relations team contacts below can assist with completion of
shareholder participation in advance of the meetings.
Galapagos would like to thank its
shareholders for their support during this unprecendented
situation. For a letter from our CEO addressing the
COVID-19 pandemic and its impact on Galapagos, please visit
www.glpg.com.
About GalapagosGalapagos
(Euronext & NASDAQ: GLPG) discovers and develops small molecule
medicines with novel modes of action, three of which show promising
patient results and are currently in late-stage development in
multiple diseases. Our pipeline comprises discovery through Phase 3
programs in inflammation, fibrosis, osteoarthritis and other
indications. Our ambition is to become a leading global
biopharmaceutical company focused on the discovery, development and
commercialization of innovative medicines. More information at
www.glpg.com.
Contact
Investors:Elizabeth GoodwinVP
Investor Relations +1 781 460 1784
Sofie Van GijselDirector Investor Relations+32
485 19 14 15ir@glpg.com
Media:Carmen VroonenSenior
Director Communications & Public Affairs+32 473 824 874
Evelyn FoxDirector Communications+31 6 53 591
999communications@glpg.com
Forward-looking statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
DisclaimerThe contents of our
website, including the annual report for the financial year 2019,
and any other website that may be accessed from our website, shall
not be deemed incorporated by reference in any filing under the
Securities Act of 1933.
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024